title: Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel.
abstract: Depending on stage and risk factors, up to 30% of patients with advanced Hodgkin lymphoma (HL) progress or relapse. Patients with pleural effusions have a particularly poor prognosis and this stage of HL is regularly resistant to chemotherapy. All currently available HL cell lines are derived from late stage HL patients. In the present study we measured the sensitivity of these HL lines against the 26 most frequently used cytostatic drugs. We used a novel fluorescent short-term survival assay where the cell was incubated with the drugs for 4 days. The precise number of differentially stained live and dead cells was determined using a custom-built automated laser confocal fluorescent microscope. We found that HL cells, independently of their origin, showed very similar sensitivity patterns for several of the drugs. All HL cell lines were highly sensitive to dactinomycin, paclitaxel and etoposide. Our data suggest that the inclusion of dactinomycin and paclitaxel into chemotherapy protocols against late stage Hodgkin lymphoma with pleural effusion may be justified.
authors.affiliation: Department of Microbiology, Tumor and Cell Biology (MTC) and Center for Integrative Recognition in the Immune System (IRIS), Karolinska Institute, Stockholm, Sweden.
authors.forename: Laszlo
authors.initials: L
authors.lastname: Markasz
authors.forename: Lorand Levente
authors.initials: LL
authors.lastname: Kis
authors.forename: Gyorgy
authors.initials: G
authors.lastname: Stuber
authors.forename: Emilie
authors.initials: E
authors.lastname: Flaberg
authors.forename: Rita
authors.initials: R
authors.lastname: Otvos
authors.forename: Staffan
authors.initials: S
authors.lastname: Eksborg
authors.forename: Henriette
authors.initials: H
authors.lastname: Skribek
authors.forename: Eva
authors.initials: E
authors.lastname: Olah
authors.forename: Laszlo
authors.initials: L
authors.lastname: Szekely
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003609:Dactinomycin / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D017239:Paclitaxel / Q000494:pharmacology*